Johnson & Johnson/$JNJ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Ticker
$JNJ
Sector
Primary listing
NYSE
Employees
138,100
Headquarters
Website
JNJ Metrics
BasicAdvanced
$429B
19.08
$9.33
0.40
$5.08
2.92%
Price and volume
Market cap
$429B
Beta
0.4
52-week high
$181.16
52-week low
$140.68
Average daily volume
8.1M
Dividend rate
$5.08
Financial strength
Current ratio
1.006
Quick ratio
0.678
Long term debt to equity
49.998
Total debt to equity
64.686
Dividend payout ratio (TTM)
53.34%
Interest coverage (TTM)
27.08%
Profitability
EBITDA (TTM)
30,255
Gross margin (TTM)
68.40%
Net profit margin (TTM)
25.00%
Operating margin (TTM)
25.16%
Effective tax rate (TTM)
17.14%
Revenue per employee (TTM)
$660,000
Management effectiveness
Return on assets (TTM)
7.61%
Return on equity (TTM)
30.21%
Valuation
Price to earnings (TTM)
19.076
Price to revenue (TTM)
4.729
Price to book
5.46
Price to tangible book (TTM)
-22
Price to free cash flow (TTM)
26.137
Free cash flow yield (TTM)
3.83%
Free cash flow per share (TTM)
6.812
Dividend yield (TTM)
2.85%
Forward dividend yield
2.92%
Growth
Revenue change (TTM)
4.68%
Earnings per share change (TTM)
-39.59%
3-year revenue growth (CAGR)
0.91%
10-year revenue growth (CAGR)
2.34%
3-year earnings per share growth (CAGR)
10.74%
10-year earnings per share growth (CAGR)
5.10%
3-year dividend per share growth (CAGR)
5.21%
10-year dividend per share growth (CAGR)
5.82%
What the Analysts think about JNJ
Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.
Bulls say / Bears say
Johnson & Johnson’s Q2 2025 adjusted EPS of $2.77 and revenue of $23.74 billion both exceeded analyst forecasts, prompting management to raise full-year sales guidance to $93.2–93.6 billion and adjusted EPS to $10.80–10.90 (Reuters)
Sales of cancer drug Darzalex reached $3.54 billion in Q2 2025—4% ahead of estimates—demonstrating the drug’s sustained market leadership and strengthening J&J’s oncology business (Reuters)
The FDA’s April 30 approval of IMAAVY™ for generalized myasthenia gravis opens a new immunology market with high unmet need, with peak sales expected to surpass $5 billion, further diversifying J&J’s innovative medicine portfolio (Reuters)
A U.S. bankruptcy judge’s April 1 rejection of Johnson & Johnson’s $10 billion talc settlement leaves over 60,000 ovarian cancer and mesothelioma claims unresolved, exposing the company to potential multi-billion dollar jury awards and lengthy litigation costs (Reuters)
Kenvue, J&J’s 2023 consumer-health spin-off, has forecast 2025 profit below Wall Street expectations and faces pressure from activist investors over its underperforming skin-health and beauty divisions, highlighting risks in J&J's decision to divest its stabilizing consumer business (FT)
Proposed U.S. pharmaceutical import tariffs, potentially reaching as high as 250%, prompted J&J’s $2 billion investment in U.S. manufacturing, emphasizing a significant risk to drug profit margins if these duties go into effect (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2025.
JNJ Financial Performance
Revenues and expenses
JNJ Earnings Performance
Company profitability
JNJ News
AllArticlesVideos
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Market Watch3 days ago
J&J Painting Recognized with 2026 Consumer Choice Award for Painting Contractor in Waterloo
Accesswire3 days ago
After a couple years in purgatory, Johnson & Johnson is now having a strong year, says Jim Cramer
CNBC Television4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Johnson & Johnson stock?
Johnson & Johnson (JNJ) has a market cap of $429B as of September 15, 2025.
What is the P/E ratio for Johnson & Johnson stock?
The price to earnings (P/E) ratio for Johnson & Johnson (JNJ) stock is 19.08 as of September 15, 2025.
Does Johnson & Johnson stock pay dividends?
Yes, the Johnson & Johnson (JNJ) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is $5.08 and the yield is 2.92%. Johnson & Johnson has a payout ratio of 53.34% on a trailing twelve-month basis.
When is the next Johnson & Johnson dividend payment date?
The next Johnson & Johnson (JNJ) dividend payment date is unconfirmed.
What is the beta indicator for Johnson & Johnson?
Johnson & Johnson (JNJ) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.